ArticlePhysiological research2025
Prevention of the Progression of lupus Nephritis in MRL/lpr Mice by Modulating miR-9-5p/Foxo1 Axis.
Article in Physiological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MiR-9-5p is up-regulated in lupus nephritis (LN) patients and targets Foxo1 that is a protective factor against renal disorders. In the current study, the role of miR-9-5p/Foxo1 LN progression was assessed and the associated mechanism was explored. The levels of LN-associated miRs were firstly detected in MRL/lpr mice. Then the effect of miR-9-5p modulation on the viability of SV40 MES 13 cells was detected. MRL/lpr mice were treated with miR agomirs or antagonists, and effects on renal structure and function were assessed. MiR-9-5p was selected as the potential target, which was up-regulated in MRL/lpr mice, contributing to the suppressed expression of Foxo1. The modulation of miR-9-5p in vitro influenced the viability of SV40 MES 13 cells. The progression of LN in mice was also associated with the increased level of miR-9-5p and the decreased level of Foxo1. The administration of miR agomirs significantly impaired renal structure and function impairments associated with LN, along with the suppressed expression of Foxo1, while antagonists improved these features by up-regulating Foxo1 level. The current study demonstrated that miR-9-5p showed LN promoting effects, which depended on the inhibition of Foxo1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.